Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results

The mutant IDH1 (mIDH1) inhibitor BAY1436032 demonstrated robust activity in preclinical AML models, supporting clinical evaluation. In the current dose-escalation study, BAY1436032 was orally administered to 27 mIDH1 AML subjects across 4 doses ranging from 300 to 1500 mg twice-daily. BAY1436032 ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Heuser, Michael, Palmisiano, Neil, Mantzaris, Ioannis, Mims, Alice, DiNardo, Courtney, Silverman, Lewis R., Wang, Eunice S., Fiedler, Walter, Baldus, Claudia, Schwind, Sebastian, Pardee, Timothy, Perl, Alexander E., Cai, Charles, Kaulfuss, Stefan, Lagkadinou, Eleni, Rentzsch, Christine, Wagner, Markus, Wilkinson, Gary, Wu, Bingyan, Jeffers, Michael, Genvresse, Isabelle, Krämer, Alwin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7584476/
https://www.ncbi.nlm.nih.gov/pubmed/32733012
http://dx.doi.org/10.1038/s41375-020-0996-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7584476/
https://www.ncbi.nlm.nih.gov/pubmed/32733012
http://dx.doi.org/10.1038/s41375-020-0996-5

Ejemplares similares